中华实验和临床病毒学杂志
中華實驗和臨床病毒學雜誌
중화실험화림상병독학잡지
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL VIROLOGY
2014年
6期
461-463
,共3页
方玉才%王秋英%潘统桧%杨燕飞%高晓磊
方玉纔%王鞦英%潘統檜%楊燕飛%高曉磊
방옥재%왕추영%반통회%양연비%고효뢰
肝炎,丙型,慢性%肝炎病毒属%RNA%干扰素α-2b%转氨酶类%肝硬化
肝炎,丙型,慢性%肝炎病毒屬%RNA%榦擾素α-2b%轉氨酶類%肝硬化
간염,병형,만성%간염병독속%RNA%간우소α-2b%전안매류%간경화
Hepatitis C,chronic%Hepatovirus%RNA%Interferon alpha 2 b%Transaminases%Liver cirrhosis
目的 观察聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎过程中肝功能、病毒复制及肝纤维化指标的改变情况.方法 检测67例慢性丙型肝炎患者在干扰素联合利巴韦林治疗开始(0周)、结束(48周)和停药12周(60周)时血清丙氨酸转氨酶(ALT)、丙肝病毒核糖核酸(HCV RNA)、透明质酸(HA)、Ⅲ型前胶原肽(PCⅢ)、Ⅳ型胶原(Ⅳ-C)和层粘连蛋白(LN)水平.结果 治疗后完全应答组(CR-S,43/67) ALT、HCV RNA及血清4项纤维化指标均显著下降(P ＜0.05或P＜0.01),部分应答组(CR-R,13/67)和无应答组(NR,11/67) ALT、HCV RNA及血清4项纤维化指标变化不明显,反跳甚至更高.结论 聚乙二醇干扰素α-2b联合利巴韦林治疗慢性丙型肝炎约65％患者完全应答,随着肝细胞炎症的改善,病毒RNA滴度、肝纤维化指标水平明显下降,表明干扰素联合利巴韦林能抑制HCV RNA复制,调节机体免疫功能,减轻肝脏炎症反应,改善肝功能,减少肝纤维化.
目的 觀察聚乙二醇榦擾素α-2b聯閤利巴韋林治療慢性丙型肝炎過程中肝功能、病毒複製及肝纖維化指標的改變情況.方法 檢測67例慢性丙型肝炎患者在榦擾素聯閤利巴韋林治療開始(0週)、結束(48週)和停藥12週(60週)時血清丙氨痠轉氨酶(ALT)、丙肝病毒覈糖覈痠(HCV RNA)、透明質痠(HA)、Ⅲ型前膠原肽(PCⅢ)、Ⅳ型膠原(Ⅳ-C)和層粘連蛋白(LN)水平.結果 治療後完全應答組(CR-S,43/67) ALT、HCV RNA及血清4項纖維化指標均顯著下降(P ＜0.05或P＜0.01),部分應答組(CR-R,13/67)和無應答組(NR,11/67) ALT、HCV RNA及血清4項纖維化指標變化不明顯,反跳甚至更高.結論 聚乙二醇榦擾素α-2b聯閤利巴韋林治療慢性丙型肝炎約65％患者完全應答,隨著肝細胞炎癥的改善,病毒RNA滴度、肝纖維化指標水平明顯下降,錶明榦擾素聯閤利巴韋林能抑製HCV RNA複製,調節機體免疫功能,減輕肝髒炎癥反應,改善肝功能,減少肝纖維化.
목적 관찰취을이순간우소α-2b연합리파위림치료만성병형간염과정중간공능、병독복제급간섬유화지표적개변정황.방법 검측67례만성병형간염환자재간우소연합리파위림치료개시(0주)、결속(48주)화정약12주(60주)시혈청병안산전안매(ALT)、병간병독핵당핵산(HCV RNA)、투명질산(HA)、Ⅲ형전효원태(PCⅢ)、Ⅳ형효원(Ⅳ-C)화층점련단백(LN)수평.결과 치료후완전응답조(CR-S,43/67) ALT、HCV RNA급혈청4항섬유화지표균현저하강(P ＜0.05혹P＜0.01),부분응답조(CR-R,13/67)화무응답조(NR,11/67) ALT、HCV RNA급혈청4항섬유화지표변화불명현,반도심지경고.결론 취을이순간우소α-2b연합리파위림치료만성병형간염약65％환자완전응답,수착간세포염증적개선,병독RNA적도、간섬유화지표수평명현하강,표명간우소연합리파위림능억제HCV RNA복제,조절궤체면역공능,감경간장염증반응,개선간공능,감소간섬유화.
Objective Observation of polyethylene glycol (peg) interferon alpha 2 b plus ribavirin treatment of chronic hepatitis C liver function,viral replication and liver fibrosis index in the process of change.Methods Detection of 67 cases of chronic hepatitis C patients in the treatment with interferon plus ribavirin end of week (0),(48 weeks) and drug withdrawal 12 weeks (60 weeks) in serum alanine aminotransferase (ALT),hepatitis C virus (HCV) RNA (HCV RNA),hyaluronic acid (HA),a former Ⅲ type collagen peptide (PC Ⅲ),collagen type Ⅳ (Ⅳ-C) and laminin (LN) level. Results Complete response after treatment group (CR-S,43/67) ALT,4 items of HCV RNA and serum fibrosis indexes were significantly decreased (P ＜ 0.05 or P ＜ 0.01),part of the response group (CR-R,13/67) and no answer (NR,11/67) ALT,4 items of HCV RNA and serum fibrosis index change is not obvious,bounce is even higher.Conclusion Polyethylene glycol interferon alpha 2 b plus ribavirin treatment of chronic hepatitis C response,about 65％ of patients completely as the improvement of liver inflammation,viral RNA drops and liver fibrosis index level declined obviously,suggest that interferon plus ribavirin can inhibit HCV RNA replication,regulate the body's immune function,reduce liver inflammation,improve liver function,reduce liver fibrosis.
